PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Cleveland Clinic research: Most statin-intolerant patients can eventually tolerate statins

Finds 72.5 percent of previously statin-intolerant patients could take the drugs on subsequent trials over 15-year study period at Cleveland Clinic

2013-09-09
(Press-News.org) Monday, September 9, 2013, Cleveland: Most patients who report statin intolerance, including muscle aches and other side effects from the cholesterol-lowering drugs, can actually tolerate drugs from this class on subsequent trials, according to research from Cleveland Clinic recently released online and forthcoming in the September issue of the American Heart Journal. The study is the largest ever to examine the effects of re-challenging statin-intolerant patients.

Statins are among the most prescribed drugs in the world and are a first-line, highly effective therapy for patients with high cholesterol, which is a major risk factor in the development of cardiovascular disease. Statins have been shown to reduce cholesterol levels by as much as 20 to 40 percent at the lowest dose level. However, in clinical trials, about 5 to 10 percent of patients have been reported as suffering from statin-related side effects like muscle pain and liver enzyme abnormalities, making them statin intolerant. In observational studies – which often incorporate patients not typically selected for clinical trials, including older patients, more women, and those with comorbidities – the rate of statin intolerance is as high as 20 percent.

In these patients, physicians often try intermittent dosing of statins, instructing patients to take the medication every other day, for instance, instead of daily, to reduce side effects.

Researchers, led by Leslie Cho, M.D., Section Head of Preventative Cardiology and Rehabilitation in the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic, analyzed the electronic medical records of 1,605 patients who were referred to Cleveland Clinic for statin intolerance between January 1995 and March 2010.

Dr. Cho and her colleagues found that 72.5 percent of patients who were previously reported to be intolerant to two or more statins were able to take drugs from the class on subsequent trials when they were overseen in Cleveland Clinic's preventative cardiology clinic and had their statin regimen carefully restarted. Further, 63.2 percent of previously statin-intolerant patients were able to tolerate a daily statin regimen, with only 9.3 percent going on intermittent statin therapy. While those patients who remained on a daily dose of statin saw their cholesterol lowered to a greater extent than those on intermittent statin dosing, Dr. Cho and her colleagues found that the intermittent group did benefit significantly from the statin therapy.

"Our study shows that patients who have experienced statin intolerance should, under the close care of their physician, continue to try other drugs in this class because there is a very good chance that they will eventually be able to tolerate long-term use of a statin and benefit from its cholesterol-lowering effects," said Dr, Cho. "Even if patients cannot tolerate a daily dose of a statin, it's possible to see a significant reduction in cholesterol levels from taking the drug less often, even as infrequently as once a week."

Still, Dr. Cho points out that, given how widely statins are prescribed, it's important to note that almost 30 percent of the patients in the study remained statin intolerant and required alternative therapies to treat their high cholesterol.

### About Cleveland Clinic Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. More than 3,000 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. The Cleveland Clinic health system includes a main campus near downtown Cleveland, more than 75 Northern Ohio outpatient locations, including 16 full-service Family Health Centers, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and, currently under construction, Cleveland Clinic Abu Dhabi. In 2012, there were 5.1 million outpatient visits throughout the Cleveland Clinic health system and 157,000 hospital admissions. Patients came for treatment from every state and from more than 130 countries. Visit us at http://www.clevelandclinic.org. Follow us at http://www.twitter.com/ClevelandClinic.

Contacts: Wyatt DuBois, 216.445.9946, duboisw@ccf.org Tora Vinci, 216.444.2412, vinciv@ccf.org


ELSE PRESS RELEASES FROM THIS DATE:

Genome of elastomeric materials creates novel materials

2013-09-09
A wide range of biologically inspired materials may now be possible by combining protein studies, materials science and RNA sequencing, according to an international team of researchers. "Biological methods of synthesizing materials are not new," said Melik C. Demirel, professor of engineering science and mechanics, Penn State. "What is new is the application of these principles to produce unique materials." The researchers looked at proteins because they are the building blocks of biological materials and also often control sequencing, growth and self-assembly. RNA ...

Synthetic speech system puts a dampener on noisy announcements

2013-09-09
Public announcements in noisy places – such as railway stations, airports, or sports venues – could become quieter and clearer in future, thanks to new research. Scientists have developed software that can alter speech before it is broadcast over speakers, making it more audible amid background noise. In a bid to improve current synthetic voice technology, researchers studied how speech was perceived by listeners. They carried out tests to pinpoint the components of speech that are most easily heard by people in a noisy place. Experts at the University of Edinburgh, ...

eButton health monitor gets a facelift

2013-09-09
PITTSBURGH—A wearable, picture-taking health monitor created by University of Pittsburgh researchers has received a recent facelift. Now, in addition to documenting what a person eats, the eButton prototype can accurately match those images against a geometric-shape library, providing a much easier method for counting calories. Published in Measurement Science and Technology, the Pitt study demonstrates a new computational tool that has been added to the eButton—a device that fastens to the shirt like a pin. Using its newly built comprehensive food-shape library, the ...

Accidental nanoparticle discovery could hail revolution in manufacturing

2013-09-09
A nanoparticle shaped like a spiky ball, with magnetic properties, has been uncovered in a new method of synthesising carbon nanotubes by physicists at Queen Mary University of London and the University of Kent. Carbon nanotubes are hollow, cylindrical molecules that can be manipulated to give them useful properties. The nanoparticles were discovered accidentally on the rough surfaces of a reactor designed to grow carbon nanotubes. Described as sea urchins because of their characteristic spiny appearance, the particles consist of nanotubes filled with iron, with ...

Workshop report explores use of mass collaboration in disaster management

2013-09-09
WASHINGTON -- The growing use of social media and other mass collaboration technologies is opening up new opportunities in disaster management efforts, but is also creating new challenges for policymakers looking to incorporate these tools into existing frameworks, according to a new report from the Commons Lab at the Woodrow Wilson International Center for Scholars. The Commons Lab, part of the Wilson Center's Science & Technology Innovation Program, hosted a September 2012 workshop bringing together emergency responders, crisis mappers, researchers, and software programmers ...

Science supporting abundant, nourishing food for a growing civilization

2013-09-09
Contact: Michael Bernstein m_bernstein@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6042 Michael Woods m_woods@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6293 American Chemical Society Science supporting abundant, nourishing food for a growing civilization INDIANAPOLIS, Sept. 8, 2013 — The diets of people in North America shed almost 1.5 billion pounds of unhealthy saturated and trans fat over the last six years thanks to a new phase in an ongoing agricultural revolution, an expert said here today. In an ...

New weapons on the way to battle wicked weeds

2013-09-09
Contact: Michael Bernstein m_bernstein@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6042 Michael Woods m_woods@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6293 American Chemical Society New weapons on the way to battle wicked weeds INDIANAPOLIS, Sept. 8, 2013 — A somber picture of the struggle against super-weeds emerged here today as scientists described the relentless spread of herbicide-resistant menaces like pigweed and horseweed that shrug off powerful herbicides and have forced farmers in some areas ...

New 'artificial nose' device can speed diagnosis of sepsis

2013-09-09
Contact: Michael Bernstein m_bernstein@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6042 Michael Woods m_woods@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6293 American Chemical Society New 'artificial nose' device can speed diagnosis of sepsis INDIANAPOLIS, Sept. 8, 2013 — Disease-causing bacteria stink — literally — and the odor released by some of the nastiest microbes has become the basis for a faster and simpler new way to diagnose blood infections and finger the specific microbe, scientists reported ...

A new approach to early diagnosis of influenza

2013-09-09
Contact: Michael Bernstein m_bernstein@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6042 Michael Woods m_woods@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6293 American Chemical Society A new approach to early diagnosis of influenza INDIANAPOLIS, Sept. 8, 2013 — A new technology is showing promise as the basis for a much-needed home test to diagnose influenza quickly, before the window for taking antiviral drugs slams shut and sick people spread the virus to others, scientists reported here today. In ...

Toward understanding the health effects of waterpipe or 'hookah' smoking

2013-09-09
Contact: Michael Bernstein m_bernstein@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6042 Michael Woods m_woods@acs.org 317-262-5907 (Indianapolis Press Center, Sept. 6-11) 202-872-6293 American Chemical Society Toward understanding the health effects of waterpipe or 'hookah' smoking lNDIANAPOLIS, Sept. 8, 2013 — With water pipes or hookahs gaining popularity in the United States and other countries, scientists today described a step toward establishing the health risks of what has been termed "the first new tobacco trend of ...

LAST 30 PRESS RELEASES:

Post-LLM era: New horizons for AI with knowledge, collaboration, and co-evolution

“Sloshing” from celestial collisions solves mystery of how galactic clusters stay hot

Children poisoned by the synthetic opioid, fentanyl, has risen in the U.S. – eight years of national data shows

USC researchers observe mice may have a form of first aid

VUMC to develop AI technology for therapeutic antibody discovery

Unlocking the hidden proteome: The role of coding circular RNA in cancer

Advancing lung cancer treatment: Understanding the differences between LUAD and LUSC

Study reveals widening heart disease disparities in the US

The role of ubiquitination in cancer stem cell regulation

New insights into LSD1: a key regulator in disease pathogenesis

Vanderbilt lung transplant establishes new record

Revolutionizing cancer treatment: targeting EZH2 for a new era of precision medicine

Metasurface technology offers a compact way to generate multiphoton entanglement

Effort seeks to increase cancer-gene testing in primary care

Acoustofluidics-based method facilitates intracellular nanoparticle delivery

Sulfur bacteria team up to break down organic substances in the seabed

Stretching spider silk makes it stronger

Earth's orbital rhythms link timing of giant eruptions and climate change

Ammonia build-up kills liver cells but can be prevented using existing drug

New technical guidelines pave the way for widespread adoption of methane-reducing feed additives in dairy and livestock

Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza

New study finds that tooth size in Otaria byronia reflects historical shifts in population abundance

nTIDE March 2025 Jobs Report: Employment rate for people with disabilities holds steady at new plateau, despite February dip

Breakthrough cardiac regeneration research offers hope for the treatment of ischemic heart failure

Fluoride in drinking water is associated with impaired childhood cognition

New composite structure boosts polypropylene’s low-temperature toughness

While most Americans strongly support civics education in schools, partisan divide on DEI policies and free speech on college campuses remains

Revolutionizing surface science: Visualization of local dielectric properties of surfaces

LearningEMS: A new framework for electric vehicle energy management

Nearly half of popular tropical plant group related to birds-of-paradise and bananas are threatened with extinction

[Press-News.org] Cleveland Clinic research: Most statin-intolerant patients can eventually tolerate statins
Finds 72.5 percent of previously statin-intolerant patients could take the drugs on subsequent trials over 15-year study period at Cleveland Clinic